Abstract
Risk of epithelial ovarian cancer (EOC) attendant to use of hormone replacement therapy (HRT) was evaluated in a population-based case-control study of newly diagnosed EOC cases (n = 256) and randomly selected population controls (n = 1122). Telephone interviews were conducted to obtain information on history of HRT and several other covariates. Multivariate adjusted odds ratio (OR) and 95% confidence intervals (CI) were derived from unconditional logistic regression. The OR for ever use of HRT was 1.39 (95% CI: 1.01-1.93) compared to never use. Long-term use (>10 years) increased risk (OR: 1.62, CI: 1.05-2.50) although the trend p-value for duration of use was of only borderline significance (p = 0.08). The relationship was stronger in women without hysterectomy (OR: 1.66, 95% CI: 1.14-2.41) or tubal ligation (OR: 1.56, 95% CI: 1.08-2.26). In this study, use of HRT is associated with an increased risk of EOC.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 124-132 |
| Number of pages | 9 |
| Journal | Cancer Detection and Prevention |
| Volume | 29 |
| Issue number | 2 |
| DOIs | |
| State | Published - 2005 |
| Externally published | Yes |
Fingerprint
Keywords
- Epidemiology
- Gynecologic cancer
- Hormone replacement therapy
- Risk factors
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk. / Mills, Paul K.; Riordan, Deborah G.; Cress, Rosemary D; Goldsmith, David F.
In: Cancer Detection and Prevention, Vol. 29, No. 2, 2005, p. 124-132.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk
AU - Mills, Paul K.
AU - Riordan, Deborah G.
AU - Cress, Rosemary D
AU - Goldsmith, David F.
PY - 2005
Y1 - 2005
N2 - Risk of epithelial ovarian cancer (EOC) attendant to use of hormone replacement therapy (HRT) was evaluated in a population-based case-control study of newly diagnosed EOC cases (n = 256) and randomly selected population controls (n = 1122). Telephone interviews were conducted to obtain information on history of HRT and several other covariates. Multivariate adjusted odds ratio (OR) and 95% confidence intervals (CI) were derived from unconditional logistic regression. The OR for ever use of HRT was 1.39 (95% CI: 1.01-1.93) compared to never use. Long-term use (>10 years) increased risk (OR: 1.62, CI: 1.05-2.50) although the trend p-value for duration of use was of only borderline significance (p = 0.08). The relationship was stronger in women without hysterectomy (OR: 1.66, 95% CI: 1.14-2.41) or tubal ligation (OR: 1.56, 95% CI: 1.08-2.26). In this study, use of HRT is associated with an increased risk of EOC.
AB - Risk of epithelial ovarian cancer (EOC) attendant to use of hormone replacement therapy (HRT) was evaluated in a population-based case-control study of newly diagnosed EOC cases (n = 256) and randomly selected population controls (n = 1122). Telephone interviews were conducted to obtain information on history of HRT and several other covariates. Multivariate adjusted odds ratio (OR) and 95% confidence intervals (CI) were derived from unconditional logistic regression. The OR for ever use of HRT was 1.39 (95% CI: 1.01-1.93) compared to never use. Long-term use (>10 years) increased risk (OR: 1.62, CI: 1.05-2.50) although the trend p-value for duration of use was of only borderline significance (p = 0.08). The relationship was stronger in women without hysterectomy (OR: 1.66, 95% CI: 1.14-2.41) or tubal ligation (OR: 1.56, 95% CI: 1.08-2.26). In this study, use of HRT is associated with an increased risk of EOC.
KW - Epidemiology
KW - Gynecologic cancer
KW - Hormone replacement therapy
KW - Risk factors
UR - http://www.scopus.com/inward/record.url?scp=17044432658&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=17044432658&partnerID=8YFLogxK
U2 - 10.1016/j.cdp.2004.11.002
DO - 10.1016/j.cdp.2004.11.002
M3 - Article
C2 - 15829372
AN - SCOPUS:17044432658
VL - 29
SP - 124
EP - 132
JO - Cancer Epidemiology
JF - Cancer Epidemiology
SN - 1877-7821
IS - 2
ER -